| In Vivo |
Delmitide (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo[2]. Delmitide (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice[2]. Animal Model: BALB/c mice (female, 9-10-week)[2] Dosage: 2.5, 5, 10 mg/kg or 0.2 mL, 10 mg/kg Administration: Oral, daily Result: Reduced the incidence of diarrhea and attenuated CPT-11-associated GI toxicity and mortality in a dose-dependent manner. Had protective effect against chemotherapy-induced GI side-effects and reduced CPT-11-induced overexpression of TNF-α, IFN-γ, and IL-12 in vivo. Preserved the intestinal mucosa morphology by maintaining villus and crypt structure and inhibited TNF-α-mediated apoptosis in the crypt compartment, thereby protecting intestinal mucosa integrity in mice. Protected mice from CPT-11-induced GI toxicity and mortality and enhanced animal survival in tumor-bearing mice. Significantly reduced the incidence and overall tumor burden in a spontaneously metastatic model.
|
